INVIVYD, INC. Class of Warrant or Right, Outstanding
INVIVYD, INC. (IVVD) had Class of Warrant or Right, Outstanding of 6.82 million shares as of 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2024-11-14
- 2024-09-30: Class of Warrant or Right, Outstanding 6.82M shares.
- 2024-06-30: Class of Warrant or Right, Outstanding 6.82M shares.
- 2024-03-31: Class of Warrant or Right, Outstanding 6.82M shares.
- 2023-09-30: Class of Warrant or Right, Outstanding 6.82M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2024-09-30 | 6.82M shares 10-Q · filed 2024-11-14 |
| 2024-06-30 | 6.82M shares 10-Q · filed 2024-08-14 |
| 2024-03-31 | 6.82M shares 10-Q · filed 2024-05-09 |
| 2023-09-30 | 6.82M shares 10-Q · filed 2023-11-09 |
| 2023-06-30 | 6.82M shares 10-Q · filed 2023-08-10 |
| 2023-03-31 | 6.82M shares 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |